Jan 13, 2025
After Deucrava 6 Mg (Deucravacitinib) was administered once daily, the steady state Cmax and AUC24 were 45 ng/mL and 473 ng x hr/mL,
seen from Spain
seen from China
seen from China
seen from United States
seen from Brazil
seen from United States
seen from United States
seen from United Kingdom
seen from China
seen from United States
seen from Yemen
seen from Norway
seen from United States
seen from United States
seen from Netherlands
seen from Yemen
seen from Yemen
seen from Venezuela
seen from United States
seen from Italy
After Deucrava 6 Mg (Deucravacitinib) was administered once daily, the steady state Cmax and AUC24 were 45 ng/mL and 473 ng x hr/mL,
Exploring the Future of Autoimmune Disease Treatments: Upcoming Drugs
What are Autoimmune Diseases? Autoimmune diseases are a diverse group of conditions where the immune system mistakenly attacks healthy cells and tissues in the body. These diseases encompass a wide range of disorders, such as Crohn’s disease, myasthenia gravis, ulcerative colitis, plaque psoriasis, and more. Amidst the ongoing COVID-19 pandemic, it’s crucial to focus on the development of novel…
View On WordPress
Two clinical trials have concluded that the drugs anifrolumab and deucravacitinib are safe and effective in the treatment of systemic lupus
Deucravacitinib: la nuova speranza approvata per la psoriasi e valutata in molte nazioni del globo
Deucravacitinib: la nuova speranza approvata per la psoriasi e valutata in molte nazioni del globo
La psoriasi è una malattia autoimmune sistemica cronica che compromette la qualità di vita e la produttività in ambito lavorativo. La psoriasi rappresenta un grave problema a livello globale, che vede almeno 100 milioni di persone in tutto il mondo colpite da una delle sue forme, di cui circa 14 milioni in Europa e 7,5 milioni negli Stati Uniti. Circa un quarto dei pazienti affetti da psoriasi…
View On WordPress
Bristol Myer Squibb’s deucravacitinib, which is an oral selective, allosteric tyrosine kinase 2 (TYK2) inhibitor has been evaluated for multiple immune-mediated diseases, including psoriasis arthritis, inflammatory bowel diseases, active discoid and subacute cutaneous lupus.